High prescription drug costs are a leading concern among Americans. Americans pay higher prices for prescription drugs than any other country in the world, with prescription drug prices in the U.S. more than 2.5 times as high as those in other similar high-income nations.
Division of Science and Public Health Policy
The Division of Science and Public Health Policy is the ASPE lead on public health and biomedical science issues and initiatives, including programmatic and policy areas that involve complex or rapidly evolving science and technology. The Division provides technical assistance on regulatory impact analysis development to HHS agencies and offices. The Division is responsible for policy coordination; long-range planning; legislative development; economic, program, and regulatory analysis; and evaluation focused on the HHS science and public health agencies – the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and Office of the Assistant Secretary for Preparedness and Response (ASPR). Examples of issue areas include:
- Biomedical innovation
- Biomedical research policy
- Medical product regulation
- Drug development, safety, availability, and pricing
- Public health and emergency preparedness, response, and recovery
- Opioid epidemic response
- Emerging infectious diseases
- Prevention of chronic diseases
- Food safety
Reports
Displaying 21 - 30 of 37. 10 per page. Page 3.
Advanced SearchASPE Issue Brief, Database, Dataset
Flexibilities in Controlled Substances Prescribing and Dispensing During the COVID-19 Pandemic
The COVID-19 pandemic had wide-ranging impacts on health care delivery, particularly services that require in-person interactions. For patients needing access to medications to treat pain or certain substance use disorders, the COVID-19 pandemic presented particular challenges for continuity of treatment.
Report
National Action Plan for Combating Antibiotic-Resistant Bacteria Progress Report: Year 5
The National Action Plan for Combating Antibiotic-Resistant Bacteria 2015 – 2020 (2015 Plan) has guided the U.S. Government’s response to combating antibiotic-resistant infections since its establishment in 2015. The U.S. Government’s Interagency Task Force for Combating Antibiotic-Resistant Bacteria (CARB) has produced four previous reports on progress toward the 2015 Plan.
ASPE Issue Brief
Trends in COVID-19 Vaccination Intentions
We document a number of key facts related to trends in COVID-19 vaccination intentions of unvaccinated adults in the United States from April 2021 to January 2022 using the Household Pulse Survey. First, among unvaccinated adults both those who were willing to vaccinate and those who were previously unwilling to vaccinate eventually vaccinated in large numbers.
ASPE Issue Brief
Demographic Characteristics of Adults Receiving COVID-19 Booster Vaccinations
This ASPE issue brief examines demographic characteristics of adults receiving booster doses of COVID-19 vaccines using data from the U.S. Census Bureau's Household Pulse Survey. As of March 9, 2022, 47.5 percent of the fully vaccinated adult population has received a booster.
Report
Cost of Generic Drug Development and Approval
The purpose of this study was to estimate the cost of generic drug development and approval. This study develops an analytical framework for examining the expected net present value (ENPV) (i.e., the difference between the present value of expected revenues over product life and cost of product development and approval) to a generic drug developer in different size drug markets.
ASPE Issue Brief
Parents’ Intentions to Vaccinate Children for COVID-19 by Child Age: Sociodemographic Factors and Reasons for Hesitancy
This ASPE issue brief examines hesitancy among parents to vaccinate children ages 5-11 and 12-17 using data from the U.S. Census Bureau's Household Pulse Survey. Overall, a larger percent of parents with children aged 5-11 are hesitant to vaccinate their children (34 percent) than parents of children aged 12-17 (21 percent).
ASPE Issue Brief
Variation in use of anti-SARS-CoV-2 monoclonal antibody therapies by social vulnerability and urbanicity
Anti-SARS-CoV-2 monoclonal antibodies are an effective treatment to prevent progression to severe COVID-19 or hospitalization in high-risk individuals. Despite the benefits offered by monoclonal antibody treatment, early reports indicated that these therapeutics were not being widely used.
Research Brief
COVID-19 Vaccination Associated with Reductions in COVID-19 Mortality and Morbidity in the United States, and an Approach to Valuing these Benefits
This ASPE Research Report models the estimated reductions in COVID-19 cases, hospitalizations, and deaths associated with COVID-19 vaccination from December 2020 through July 2021. To download the Research Report, please download the PDF to the right under “Files”. To explore our dashboard that presents the Report’s results, please see below.
ASPE Issue Brief
U.S. Department of Health and Human Services Overdose Prevention Strategy
From 1999 through 2019, there were more than 840,000 drug overdose deaths in the United States. The crisis has continually evolved and escalated, including during the COVID-19 pandemic, when an estimated 93,000 persons lost their lives to drug overdose in 2020--approximately a 30% increase over the year prior.